Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)
- Datasheet
- References (4)
- Protocols
Overview
-
Product nameAnti-HLA DR + DP + DQ antibody [CR3/43]
See all HLA DR + DP + DQ primary antibodies -
DescriptionMouse monoclonal [CR3/43] to HLA DR + DP + DQ
-
Host speciesMouse
-
SpecificityThe gene of the human histocompatibility complex class II consists of at least four subregions: HLADP,DQ, and DR, containing a minimum of one alpha and one beta chain. This antibody reacts with the beta-chain of all products of the gene subregions DP, DQ, and DR.
-
Tested applicationsSuitable for: IHC-P, IP, WBmore details
-
Species reactivityReacts with: Human
-
Immunogen
Tissue, cells or virus corresponding to Human HLA DR + DP + DQ. Raised against tonsil cells of human origin
-
General notes
This antibody principally labels B cells, interdigitating reticulum cells, Langerhans’ cells and manymacrophages.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferpH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading... -
PurityProtein G purified
-
Primary antibody notesThis antibody principally labels B cells, interdigitating reticulum cells, Langerhans’ cells and manymacrophages.
-
ClonalityMonoclonal
-
Clone numberCR3/43
-
IsotypeIgG1
-
Light chain typekappa
-
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab7856 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P | Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. | |
| IP | Use at an assay dependent concentration. | |
| WB | 1/500. Detects a band of approximately 30 kDa (predicted molecular weight: 27 kDa). |
Target
-
FunctionBinds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
-
Sequence similaritiesBelongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain. -
Cellular localizationCell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
- Information by UniProt
-
Database links
- Entrez Gene: 3115 Human
- Entrez Gene: 3117 Human
- Entrez Gene: 3119 Human
- Entrez Gene: 3122 Human
- Entrez Gene: 3123 Human
- Entrez Gene: 3125 Human
- Entrez Gene: 3126 Human
- Entrez Gene: 3127 Human
see all -
Alternative names
- CD antibody
- CELIAC 1 antibody
- CELIAC1 antibody
see all
Images
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)](https://www.abcam.com/ps/products/7/ab7856/Images/HLA-DR-DP-DQ-Primary-antibodies-ab7856-3.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)IHC image of ab7856 staining in human tonsil formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab7856, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
![Western blot - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)](https://www.abcam.com/ps/products/7/ab7856/Images/HLA-DR-DP-DQ-Primary-antibodies-ab7856-2.jpg)
Western blot - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)All lanes : Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856) at 1/500 dilution
Lane 1 : U-87 MG (Human glioblastoma astrocytoma) Whole Cell Lysate
Lane 2 : Human liver tissue lysate - total protein (ab29889)
Lane 3 : Lung (Human) Tissue Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Predicted band size: 27 kDa
Observed band size: 30 kDa why is the actual band size different from the predicted? -
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)](https://www.abcam.com/ps/products/7/ab7856/Images/ab7856-305369-ab785653270.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLA DR + DP + DQ antibody [CR3/43] (ab7856)This image is courtesy of an anonymous AbreviewAb7856 staining HLA DR+DP+DQ in Human Colorectal tissue sections by Immunohistochemistry. Antigen retrieval was by heat mediation at pH6 for 20minutes. Samples were fixed with formaldehyde and blocked with 10% hydrogen peroxide for 5 minutes. Samples were incubated with primary antibody at 1/100 dilution for 15 minutes. HRP rabbit polyclonal polymer refine detection kit was used as the secondary antibody.
References
This product has been referenced in:
- Campbell MJ et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28 (2017). Read more (PubMed: 27785654) »
- Pandya H et al. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci 20:753-759 (2017). Read more (PubMed: 28253233) »
